Strategic Partnerships Salvia BioElectronics is actively expanding its U.S. and EU clinical development efforts for MySalvia Therapy with notable leadership appointments in the U.S. market. This creates an opening to propose collaboration with contract research organizations, regional distributors, hospitals, and academic medical centers to accelerate regulatory clearance, pilot programs, and early commercialization.

Clinical Momentum With a $60M Series B financing and ongoing clinical evaluation of an implantable neuromodulation device for resistant migraine, buyers and investors will be looking for validated clinical outcomes and payer strategies. This presents opportunities to introduce trial-ready devices, companion diagnostics, and outcome data packages to connect clinical value to reimbursement discussions.

Neuromodulation Focus The MySalvia Therapy platform targets key nerves involved in migraine via ultra-thin implants activated by a wearable. This positions Salvia as a potential partner for neurostimulation hardware suppliers, software integrators, and care pathway developers seeking precision neuromodulation solutions for refractory patient populations.

Global Market Expansion Operating in Europe and the United States with recognized leadership and recent industry awards, Salvia is positioned to accelerate market entry and scale. There is potential for regional distributors, clinical sites, and reimbursement consultants to support market access, post-market surveillance, and physician education initiatives.

Funding Reality With revenue in the low to mid single digits and substantial funding already raised, Salvia represents a compelling client for device manufacturers, contract manufacturers, and strategic investors seeking co-development, manufacturing partnerships, or strategic alliances to accelerate production and commercialization timelines.